An mTORC1 to HRI signaling axis promotes cytotoxicity of proteasome inhibitors in multiple myeloma

Multiple myeloma (MM) causes approximately 20% of deaths from blood cancers. Notwithstanding significant therapeutic progress, such as with proteasome inhibitors (PIs), MM remains incurable due to the development of resistance. mTORC1 is a key metabolic regulator, which frequently becomes dysregulat...

Descripción completa

Detalles Bibliográficos
Autores principales: Darawshi, Odai, Muz, Barbara, Naamat, Shiri Gershon, Praveen, Bellam, Mahameed, Mohamed, Goldberg, Karin, Dipta, Priya, Shmuel, Miriam, Forno, Francesca, Boukeileh, Shatha, Pahima, Hadas, Hermann, Julia, Raab, Marc S., Poos, Alexandra M., Weinhold, Niels, Rosenbluh, Chaggai, Gatt, Moshe E., Palm, Wilhelm, Azab, Abdel Kareem, Tirosh, Boaz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9674573/
https://www.ncbi.nlm.nih.gov/pubmed/36400754
http://dx.doi.org/10.1038/s41419-022-05421-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9674573/
https://www.ncbi.nlm.nih.gov/pubmed/36400754
http://dx.doi.org/10.1038/s41419-022-05421-4

Ejemplares similares